Successful Treatment of Child Neuro-Behcet's Disease with Infliximab.
10.4078/jrd.2014.21.4.209
- Author:
Ji Ae HUR
1
;
Dong Soo KIM
;
Ki Hwan KIM
Author Information
1. Department of Pediatrics, Severance Children's Hospital, Yonsei University College of Medicine, Seoul, Korea. khkim99@yuhs.ac
- Publication Type:Case Report
- Keywords:
Child;
Neuro-Behcet disease;
Infliximab
- MeSH:
Adolescent;
Antibodies, Monoclonal;
Child*;
Female;
Humans;
Recurrence;
Skin Ulcer;
Stomatitis, Aphthous;
Systemic Vasculitis;
Tumor Necrosis Factor-alpha;
Infliximab
- From:Journal of Rheumatic Diseases
2014;21(4):209-213
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Behcet's disease is a systemic vasculitis, characterized by recurrent oral aphthous ulcers, recurrent genital ulcers, skin lesion, and ocular involvement. Monoclonal antibody to the tumor necrosis factor-alpha (TNF-alpha) is considered as a possible therapeutic approach to achieve clinical improvement, preventing relapse in Behcet's disease refractory to conventional anti-inflammatory drugs or immunosuppressive durgs. We report the use of infliximab, which is one of the TNF-alpha monoclonal antibodies, in a 17-year-old girl with Behcet's disease exhibiting severe mucocutaneous, ocular and neurological involvement refractory to standard treatment.
